Shire to Sell Oncology Unit for $2.4 Billion to Servier

Shire to Sell Oncology Unit for $2.4 Billion to Servier

Shire Plc (LON:SHP) has agreed to sell off its oncology division to French pharma group Servier for US$2.4bn, raising doubts over the likelihood of a bid from Japanese drugmaker Takeda.

But the move also means Shire becomes less attractive to Takeda, which has until 25 April to formally announce a takeover bid under United Kingdom stock market rules, after expressing an interest earlier this month. One analyst said that the unit was considered to be non-core for Shire.

In addition, Takeda Pharmaceutical Co Ltd is still now in the process of considering approaching Shire with an offer to acquire the group, after Nikkei reported earlier in April that Takeda could value Shire at USD55 billion. A Takeda spokesman declined to comment. The drugs industry has seen a surge in dealmaking this year as large players look for promising assets to improve their pipelines, but a Takeda-Shire transaction would be by far the biggest yet.

At the end of last week, a report from Reuters citing two sources with direct knowledge of the matter claimed Takeda has even gone so far as sounding out potential lenders to help fund the deal.

Shire chief executive Flemming Ornskov said the sale of the oncology business to Servier demonstrated the value embedded in Shire as shares in the company rose 0.5 per cent as markets opened.

Shire gained as much as 3.5 percent to 3,732 pence in early trading in London.

Jefferies analysts said the sale "should boost Shire's negotiating position on asking price in the current offer period with Takeda". Ironically, Shire itself relocated its corporate headquarters to Ireland for tax reasons.

Last year, Shire's revenues doubled following the takeover to 3.57 billion USA dollars (£2.52 billion), the bulk of which came from the Baxalta business.

The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase) for acute lymphoblastic leukaemia (ALL), as well as ex-US rights to pancreatic cancer therapy Onivyde (irinotecan pegylated liposomal formulation) and long-acting Oncaspar follow-up calaspargase pegol - under FDA review for ALL.

Related Articles

  • Handelsbanken Fonder AB Invests $1.13 Million in Anthem Inc (ANTM) Stock

    The company reported $1.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.25 by $0.04. IFM Investors Pty Ltd bought a new stake in shares of Anthem during the fourth quarter worth approximately $483,000.
    Foster will not participate in 49ers team activities

    Foster will not participate in 49ers team activities

    But Coyle is recovering from shoulder surgery and isn't expected to be cleared for practice until later in the offseason. As a result, it was up to the 49ers as to whether he would participate in any offseason workouts.

    Polaris Industries Target of Unusually High Options Trading (NYSE:PII)

    The Manufacturers Life Insurance Company increased its holdings in shares of Polaris Industries by 4.0% during the fourth quarter. The stock has "Buy" rating by Sandler O'Neill on Thursday, February 8. "Buy" rating has 2, "Sell" are 0, while 12 are "Hold".
  • CBI to grill ex-UCO bank CMD for graft

    CBI to grill ex-UCO bank CMD for graft

    On 14 April, CBI booked Kaul and others in connection with an alleged Rs 621-crore loan fraud which has caused a loss of over Rs737 crore to the bank.

    On May, 2 Cirrus Logic, Inc. (CRUS) EPS Estimated At $0.46

    Amundi Pioneer Asset Management Inc. bought a new position in shares of Cirrus Logic during the 4th quarter worth about $100,000. Needham & Company LLC lowered Cirrus Logic from a "buy" rating to a "hold" rating in a research report on Tuesday, February 6th.

    $0.37 EPS Expected for Vishay Intertechnology, Inc. (VSH)

    P/E is a popular valuation ratio of a company's current share price compared to its per-share earnings (trailing twelve months). TheStreet downgraded shares of Vishay Intertechnology from an a- rating to a c+ rating in a report on Tuesday, February 6th.
  • JD Wetherspoon shuts down social media accounts amidst trolling and racism

    JD Wetherspoon shuts down social media accounts amidst trolling and racism

    The firm said its decision had been influenced by the "trolling" of MPs and concerns regarding the "misuse of personal data". Instead, he directed interested customers to the chain's printed magazine, Wetherspoons News .
    Married woman gang-raped in Uttar Pradesh village

    Married woman gang-raped in Uttar Pradesh village

    It was then that her family approached the police. "She said that she was unconscious thereafter", the officer told TOI. She initially lived with her family in the same locality in Delhi's Sultanpuri, where the suspect live with his family.
    Ola to deploy 10000 electric vehicles in 12 months

    Ola to deploy 10000 electric vehicles in 12 months

    Ltd., stated that it is negotiating with various state governments, automakers, and battery producers to meet its goal. The company said it will further expand its EV fleet to three other Indian cities but did not disclose the names.
  • Lavrov hopes West won't follow Iraqi or Libyan scenarios in Syria

    Lavrov hopes West won't follow Iraqi or Libyan scenarios in Syria

    "God forbid anything adventurous will be done in Syria following the Libyan and Iraqi experience", Mr Lavrov said. Now, I hope, no one will gamble on embarking on such a risky venture.
    Remarks against Yogi Adityanath an emotional outburst: Dinesh Gundu Rao

    Remarks against Yogi Adityanath an emotional outburst: Dinesh Gundu Rao

    The state unit saffron party took to Twitter saying, "Dinesh Gundu Rao said Yogi Adityanath must be beaten with chappals. The BJP came down heavily on these statements and made a decision to launch a state wide agitation against the comments.

    Walmart (NYSE:WMT) Receives New Coverage from Analysts at Loop Capital

    Raymond James Financial Advsr Inc has invested 0.79% in Amazon.com, Inc. 357,866 are held by Envestnet Asset Management. The retailer reported $1.33 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.37 by ($0.04).